a4090y
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February
2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
25
February 2025 - “Board Change”
|
99.1
Haleon plc: Board Change
25 February 2025: Haleon
plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces the
following change to the Board.
Following the reduction of Pfizer Inc.'s shareholding in
Haleon plc below 10%, and in line with the Pfizer Relationship
Agreement with Haleon plc, Bryan Supran, Non-Executive Director
and representative of Pfizer Inc., stepped down from the Board
on 25 February 2025.
Sir Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to
thank Bryan for his contributions to the Board's discussions and
for being part of the Haleon journey from the initial joint-venture
in 2019 through demerger to today. We wish him all the very best
for the future."
The Company confirms that there is no further information to be
disclosed under the requirements of UKLR 6.4.6R.
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans five major categories - Oral Health, Pain
Relief, Respiratory Health, Digestive Health and Other, and
Vitamins, Minerals and Supplements (VMS). Its long-standing brands
- such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin,
Polident, parodontax and Centrum - are built on trusted science,
innovation and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
Date: February 25,
2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
エドガーで原本を確認する
